FDA approves new weight-loss pill Foundayo

In this article:

• What is it?
• Why it matters
• Cost
• Foundayo vs. Wegovy
• Bottom line

In this article

• What is it?
• Why it matters
• Cost
• Foundayo vs. Wegovy
• Bottom line

A new weight-loss pill is poised to shake up the booming GLP-1 market and take on Novo Nordisk’s blockbuster Wegovy. The U.S. Food and Drug Administration has approved Foundayo (orforglipron), making it only the second GLP-1 pill cleared for weight loss in the United States. Developed by Eli Lilly and Co., the once-daily oral medication offers an alternative to injectable treatments and enters a fast-growing space dominated by drugs including Wegovy and Zepbound. Approved under the FDA’s National Priority Voucher pilot program, Foundayo could expand access to GLP-1 therapies as demand for weight-loss medications continues to surge.

What is Foundayo?

Foundayo (orforglipron) is an oral glucagon-like peptide-1 (GLP-1) receptor agonist that is indicated to be used in combination with a reduced-calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long-term in adults with obesity or adults who are overweight in the presence of at least one weight-related comorbid condition. It is designed to help regulate appetite, slow digestion, and support weight loss. Like other medications in this class, it works by mimicking hormones that signal fullness and help control blood sugar.

Unlike earlier GLP-1 treatments that require injections, Foundayo is taken as a once-daily tablet and can be used with or without food. Treatment starts at 0.8 mg daily, with increases over time. After at least 30 days, the dose may be raised to 2.5 mg, then to 5.5 mg after another 30 days. If needed, patients can continue increasing to 9 mg, 14.5 mg, or 17.2 mg, with at least 30 days between each adjustment to assess tolerance, and hopefully, minimize side effects with dose increases. Dose increases should only be made under the supervision of the healthcare provider.

In the 72-week ATTAIN-1 clinical trial, participants taking the highest dose of Foundayo lost an average of 27.3 pounds, compared with 2.2 pounds among those taking a placebo (inactive treatment).

Why this approval matters

The FDA’s approval of Foundayo comes just months after the agency cleared an oral version of Wegovy (semaglutide), marking a notable shift in how GLP-1 medications can be used for weight loss. Until recently, these treatments were only available as injections. (Another oral form of semaglutide, Rybelsus, has been available since 2019, but only for treating Type 2 diabetes.)

With Foundayo’s approval, patients now have a second pill-based weight-loss option, a change that could broaden access and appeal. For some, the availability of a daily tablet may ease hesitation around starting treatment, particularly for those uncomfortable with injections.

In a statement released by Eli Lilly, Deborah Horn, DO, director of the Center for Obesity Medicine at McGovern Medical School at UTHealth Houston, emphasized the added flexibility this option may offer.

“People living with obesity need treatment options that meet them where they are – and for many, a once-daily pill that can be taken with no food or water restrictions can offer them greater flexibility in how they approach their treatment,” Horn said. “With Foundayo, we now have an oral option that delivered an average of 12.4% weight loss at the highest dose in clinical trials – addressing both the clinical realities of obesity and the practical challenges patients face every day.”

Cost and availability

Patients won’t have to wait long to access Foundayo. Eli Lilly and Company says the medication will begin shipping on April 6, 2026, making it quickly available to eligible patients in the U.S.

Pricing will vary depending on coverage. For self-pay customers, the starting 0.8 mg dose will cost $149 per month through the LillyDirect program. Patients with commercial insurance may pay as little as $25 per month when using the Foundayo Savings Card, if their plan covers the medication. These savings programs are not available to people enrolled in government-funded plans such as Medicare or Medicaid. SingleCare coupons can offer savings, with no eligibility requirements.

How do Foundayo and Wegovy compare?

In late March, the Associated Press reported that oral Wegovy had already generated more than 600,000 prescriptions, signaling strong early demand for a pill-based GLP-1 option. Now, Foundayo is entering the same space, setting up the first real competition among oral weight-loss drugs in this class.

As oral GLP-1 medications begin to gain traction, patients and providers now have more than one pill-based option to consider. While separate clinical trials suggest oral semaglutide may lead to slightly higher average weight loss, those results aren’t directly comparable. In a head-to-head study by Eli Lily, Foundayo showed superior weight loss.

While both Foundayo and oral Wegovy aim to support weight loss, they differ in dosing flexibility, effectiveness, cost, and ease of use, all factors that may shape real-world decisions. Here’s how the two compare.

Bottom line

Foundayo may be the latest GLP-1 medication to reach the U.S. market, but it likely won’t be the last. A growing pipeline of obesity treatments, including next-generation options like Eli Lilly’s triple agonist retatrutide, signals that more choices, and potentially more effective ones, are on the way.

For now, having multiple oral GLP-1 options could make treatment more accessible and appealing. Still, these medications aren’t one-size-fits-all. Anyone considering a GLP-1 should talk with a healthcare provider to weigh factors such as overall health, weight-loss goals, cost, and long-term use.

Safety matters, too. Foundayo, like other drugs in this class, isn’t appropriate for people with certain thyroid cancers and can cause side effects ranging from mild gastrointestinal issues to more serious risks such as pancreatitis, stomach problems, and low blood sugar.